Wu Wei, Qian Liyuan, Dai Jing, Ding Boni, Chen Xuedong
Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China
Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Feb 28;42(2):147-153. doi: 10.11817/j.issn.1672-7347.2017.02.005.
OBJECTIVE: To study the expressions and the clinical significance of chemokine CXCL12 and its receptor CXCR4, CXCR7 in the human breast carcinoma (BC) with different molecular subtypes. Methods: The mRNA expressions of CXCL12, CXCR4 and CXCR7 in tissues from 80 patients with different molecular subtype of BC were measured by qRT-PCR. The protein expressions of CXCL12, CXCR4 and CXCR7 in paraffin-embedded samples from 160 patients with different molecular subtypes were detected by immunohistochemical staining. Results: The mRNA expression levels of CXCL12, CXCR4 and CXCR7 in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues (all P<0.05), but their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues. The positive expression rates of CXCL12 protein in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues (all P<0.05), while their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues.
High expressions of the gene CXCL12 and its receptor CXCR4 and CXCR7 in HER-2 positive BC and TNBC may be closely associated with their poor prognosis. Inhibition of their expressions in HER-2 positive BC and TNBC may provide a strategy for treating BC in clinic.
研究趋化因子CXCL12及其受体CXCR4、CXCR7在不同分子亚型人乳腺癌（BC）中的表达及临床意义。
采用qRT-PCR检测80例不同分子亚型BC患者组织中CXCL12、CXCR4和CXCR7的mRNA表达。采用免疫组化染色检测160例不同分子亚型患者石蜡包埋样本中CXCL12、CXCR4和CXCR7的蛋白表达。
HER-2阳性BC和三阴乳腺癌（TNBC）组织中CXCL12、CXCR4和CXCR7的mRNA表达水平显著高于腔面A型和腔面B型BC组织（均P<0.05），但在腔面A型和腔面B型BC组织之间或HER-2阳性BC与TNBC组织之间其表达无差异。HER-2阳性BC和TNBC组织中CXCL12蛋白的阳性表达率显著高于腔面A型和腔面B型BC组织（均P<0.05），而在腔面A型和腔面B型BC组织之间或HER-2阳性BC与TNBC组织之间其表达无差异。
HER-2阳性BC和TNBC中基因CXCL12及其受体CXCR4和CXCR7的高表达可能与其预后不良密切相关。抑制HER-2阳性BC和TNBC中它们的表达可能为临床治疗BC提供一种策略。
